Amgen Inc.

249.57+0.6300+0.25%Vol 1.08M1Y Perf 14.14%
Apr 13th, 2021 15:15 DELAYED
BID249.57 ASK249.70
Open249.15 Previous Close248.94
Pre-Market248.94 After-Market-
 - -%  - -
Target Price
259.29 
Analyst Rating
Moderate Buy 2.11
Potential %
3.94 
Finscreener Ranking
★★     46.98
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★     51.17
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★+     58.38
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
★★+     44.32
Market Cap143.70B 
Earnings Rating
Sell
Price Range Ratio 52W %
59.16 
Earnings Date
27th Apr 2021

Today's Price Range

247.09250.35

52W Range

210.28276.69

5 Year PE Ratio Range

13.2078.10

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
-0.06%
1 Month
8.07%
3 Months
4.71%
6 Months
4.72%
1 Year
14.14%
3 Years
45.17%
5 Years
57.46%
10 Years
391.73%

TickerPriceChg.Chg.%
AMGN249.570.63000.25
AAPL134.423.18002.42
GOOG2 275.7320.94000.93
MSFT258.542.63001.03
XOM55.780.28000.50
WFC39.90-0.8700-2.13
JNJ159.60-2.0400-1.26
FB311.27-0.2700-0.09
GE13.53-0.0600-0.44
JPM154.83-1.1200-0.72
Financial StrengthValueIndustryS&P 500US Markets
1.30
1.80
0.78
3.51
7.40
Leverage Ratio 6.40
ProfitabilityValueIndustryS&P 500US Markets
74.60
37.00
51.10
37.90
28.19
RevenueValueIndustryS&P 500US Markets
19.26B
33.45
2.97
2.24
DividendsValueIndustryS&P 500US Markets
2.83
7.04
11.46
14.64
Payout ratio50.00
Earnings HistoryEstimateReportedSurprise %
Q04 20203.363.8113.39
Q03 20203.754.3716.53
Q02 20203.814.2511.55
Q01 20203.704.1712.70
Q04 20193.443.645.81
Q03 20193.513.664.27
Q02 20193.583.9710.89
Q01 20193.453.563.19
Earnings Per EndEstimateRevision %Trend
3/2021 QR4.03-5.84Negative
6/2021 QR4.32-4.85Negative
12/2021 FY16.74-1.47Negative
12/2022 FY18.22-1.67Negative
Next Report Date27th Apr 2021
Estimated EPS Next Report4.03
Estimates Count10
EPS Growth Next 5 Years %8.40
Volume Overview
Volume1.08M
Shares Outstanding575.80M
Trades Count22.97K
Dollar Volume701.96M
Avg. Volume2.66M
Avg. Weekly Volume1.48M
Avg. Monthly Volume2.82M
Avg. Quarterly Volume2.67M

Amgen Inc. (NASDAQ: AMGN) stock closed at 248.94 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 1.72M shares and market capitalization of 143.70B. Is a component of S&P 500, NASDAQ 100, Dow Jones 30, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 24300 people. Amgen Inc. CEO is Robert A. Bradway.

The one-year performance of Amgen Inc. stock is 14.14%, while year-to-date (YTD) performance is 8.27%. AMGN stock has a five-year performance of 57.46%. Its 52-week range is between 210.28 and 276.69, which gives AMGN stock a 52-week price range ratio of 59.16%

Amgen Inc. currently has a PE ratio of 20.00, a price-to-book (PB) ratio of 15.11, a price-to-sale (PS) ratio of 7.44, a price to cashflow ratio of 13.90, a PEG ratio of 2.32, a ROA of 11.35%, a ROC of 19.06% and a ROE of 72.86%. The company’s profit margin is 28.19%, its EBITDA margin is 51.10%, and its revenue ttm is $19.26 Billion , which makes it $33.45 revenue per share.

Of the last four earnings reports from Amgen Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $4.03 for the next earnings report. Amgen Inc.’s next earnings report date is 27th Apr 2021.

The consensus rating of Wall Street analysts for Amgen Inc. is Moderate Buy (2.11), with a target price of $259.29, which is +3.94% compared to the current price. The earnings rating for Amgen Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Amgen Inc. has a dividend yield of 2.83% with a dividend per share of $7.04 and a payout ratio of 50.00%.

Amgen Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 7.26, ATR14 : 6.00, CCI20 : 42.49, Chaikin Money Flow : 0.27, MACD : -1.26, Money Flow Index : 42.64, ROC : 1.41, RSI : 45.95, STOCH (14,3) : 40.09, STOCH RSI : 1.00, UO : 53.86, Williams %R : -59.91), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Amgen Inc. in the last 12-months were: David M. Reese (Option Excercise at a value of $125 787), Jonathan P. Graham (Sold 11 110 shares of value $2 627 625 ), Robert A. Bradway (Option Excercise at a value of $11 440 325), Robert Sanders Williams (Sold 1 850 shares of value $443 286 ), Ronald D. Sugar (Option Excercise at a value of $761 820), Ronald D. Sugar (Sold 13 000 shares of value $3 089 860 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
10 (43.48 %)
11 (45.83 %)
11 (47.83 %)
Moderate Buy
2 (8.70 %)
2 (8.33 %)
1 (4.35 %)
Hold
10 (43.48 %)
10 (41.67 %)
10 (43.48 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (4.35 %)
1 (4.17 %)
1 (4.35 %)
Summary RatingModerate Buy
2.11
Moderate Buy
2.06
Moderate Buy
2.07

Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (approved 2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine). Amgen's own biosimilar portfolio includes key products Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

CEO: Robert A. Bradway

Telephone: +1 805 447-1000

Address: One Amgen Center Drive, Thousand Oaks 91320-1799, CA, US

Number of employees: 24 300

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

61%39%

Bearish Bullish

57%43%

Bearish Bullish

59%41%

News

Stocktwits